海普瑞(09989.HK)持股公司提交有關關鍵腎保護及血糖控制市場新知識產權申請
海普瑞(09989.HK)公布,公司持有約38.5%股份的Resverlogix宣布根據其重大發現擴大新知識產權申請,即當Apabetalone與鈉–葡萄糖協同轉運蛋白-2(SGLT2)抑制劑(一類領先的口服抗糖尿病治療方法)聯合用藥,可發揮協同作用,顯著改善腎功能及血糖控制。
集團指,鑒於BETonMACE3期試驗的有關發現超出預期,Resverlogix已提交兩項新增臨時專利申請,進一步強化其知識產權組合。於心血管健康領域,Apabetalone在單獨用藥及與SGLT2抑制劑聯合用藥方面均已擁有獲授予及待審核的知識產權。
集團提到,其擁有RVX-208 (Apabetalone)的大中華區獨家開發和商業權,認為額外兩項新的專利申請將延長候選藥物的潛在生命週期,顯著提高RVX-208 (Apabetalone)創新療法的整體價值,並進一步加強於大中華地區的開發和商業化計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.